Prof Dr Klemens Joos back as CEO of the EUTOP Group

14.5.2025 13:21:06 CEST | news aktuell GmbH | Press Release

Share
Prof Dr Klemens Joos photographed by Laurence Chaperon
Prof Dr Klemens Joos photographed by Laurence Chaperon

Brussels - Prof Dr Klemens Joos (56) has been back at the helm of the EUTOP Group as CEO since 13 May 2025. The background to this is an ambitious growth strategy up to 2035 for the EUTOP Group, which he founded in 1990 while studying business administration at the Ludwig Maximilian University (LMU) in Munich. Just one year after its foundation, the company had a representative office in Brussels. Today, the EUTOP Group has subsidiaries or representative offices in the capitals of all major European Union member states in addition to Brussels.

Prof Dr Klemens Joos is also an honorary professor of ‘Business Administration - Political Stakeholder Management’ at the Technical University of Munich (TUM).

Enquiries & Contact:

Press department
EUTOP Group
+49 89 323700-0
eutop@eutop.eu

Images

Prof Dr Klemens Joos photographed by Laurence Chaperon
Prof Dr Klemens Joos photographed by Laurence Chaperon
Download

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Fiscal strength doesn't guarantee public goods delivery, US study finds21.10.2026 09:28:38 CEST | Press Release

New York/DNA - A newly released study of US state government performance found strong partisan and regional patterns within three pillars of governance: democratic accountability, state capacity and public goods provision. Yet, the US states’ outcomes differ in important ways from international comparisons, as the three governance dimensions show limited correlation, the researchers found. The report, “The Governance Performance of the Fifty States: The U.S. Berggruen Governance Index”, applies the research team’s “governance triangle” from past global country rankings to the 50 US states. The report has now been presented to the public at Columbia University in New York. “Unlike in the Berggruen Governance Index’s cross-national comparisons, where the three dimensions are broadly correlated, in the 50 U.S. states they often run counter to each other,” the authors conclude. “This may seem counterintuitive, as one might expect a well-governed state to finish high on all three and a poor

Grünenthal advances proprietary Nociceptin Receptor (NOP) Agonist into Phase II trial in acute pain20.10.2026 09:23:41 CEST | Press Release

Potential first-in-class, selective nociceptin receptor (NOP) agonist that aims to provide safe, effective treatment for moderate to severe acute pain. Following successful Phase I results earlier this year demonstrating an excellent safety profile, the program has now progressed to Phase II. The randomized, double-blind, double-dummy, placebo- and active controlled, 2-part Phase II trial will evaluate the safety, tolerability and efficacy of this novel NOP agonist in patients post bunionectomy surgery. Grünenthal anticipates reporting results in early 2028.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye